kidney cancer

Jeffrey Rathmell, PhD, and Melissa Wolf, PhD. (photo by Susan Urmy)
April 22, 2024

Study reveals potential new way to stop a common kidney cancer

Vanderbilt researchers have identified cancer cell-specific genetic alterations that reprogram the immune “landscape,” thereby driving tumor growth, and discovered a potential new drug target for stopping it.

By Bill Snyder
February 27, 2024

Multi-institutional study of Wilms tumor facilitates enrollment, optimizes treatment

Multi-institutional study finds that enrollment and outcomes were similar across various groups of children participating in therapeutic trials for Wilms tumor — the most common pediatric kidney cancer worldwide.

By Leigh MacMillan
October 31, 2023

VUMC’s Kimryn Rathmell wins Doris Duke Foundation Paragon Award

Kimryn Rathmell, MD, PhD, chair of Medicine at Vanderbilt University Medical Center, has received the Paragon Award for Research Excellence from the Doris Duke Foundation.

By Bill Snyder
Frank Mason, PhD, left, Kimryn Rathmell, MD, PhD, and their colleagues have identified an early event in the development of cancer, one that could lead to new ways to prevent it. (photo by Erin O. Smith)
September 20, 2023

VUMC study reveals critical first steps to cancer

A new study by Vanderbilt researchers provides a remarkably detailed view of the earliest events leading to the development of cancer, and of potential new ways to prevent it.

By Bill Snyder
February 17, 2022

Grant to support Haake’s research on kidney cancer

Kure It Cancer Research has awarded a $200,000 grant to support kidney cancer research by Vanderbilt’s Scott Haake, MD.

By Tom Wilemon
May 24, 2021

Analysis reveals macrophages associated with kidney cancer recurrence

A white blood cell, the TREM2/APOE/C1Q-positive macrophage, has been identified as a potential biomarker to predict recurrence of the most common type of kidney cancer and as a possible target for drug development.

By Tom Wilemon
November 10, 2020

Study underscores importance of personalized medicine in kidney cancer

A new study sheds light on how molecular subsets within the tumors of kidney cancer patients determine treatment outcomes and underscores the importance of personalized medicine in making therapy decisions.
By Tom Wilemon
November 6, 2019

Rathmell receives 2019 Eugene P. Schonfeld Award

The Kidney Cancer Association is recognizing the research accomplishments and leadership achievements of W. Kimryn Rathmell, MD, PhD, with its top honor, the Eugene P. Schonfeld Award.
By Tom Wilemon
February 28, 2019

Achilles’ heel for kidney cancer

The discovery that kidney cells with mutations in a certain gene are sensitive to therapies called PI3K inhibitors opens new opportunities for applying precision medicine to cancer treatment.
By VUMC News and Communications
May 10, 2018

Grant bolsters kidney cancer immunotherapy research

W. Kimryn Rathmell, MD, PhD, Cornelius Abernathy Craig Professor of Medicine and director of the Division of Hematology and Oncology at Vanderbilt-Ingram Cancer Center (VICC), has received a grant to research the role of immunosuppression in the tumor microenvironment for kidney cancer.
By Doug Campbell
August 17, 2017

Kidney cancer patient, survivor event set for Sept. 9

Vanderbilt-Ingram Cancer Center (VICC) will sponsor an educational conference for kidney cancer patients, survivors and family members Saturday, Sept. 9, 8 a.m. – 2 p.m., in the Preston Research Building, Suite 898.
By VUMC News and Communications
September 2, 2016

Kidney cancer educational conference at VICC set Sept. 10

Kidney cancer patients, family members, health care providers and members of the public are invited to attend a free educational workshop about the disease to be held at Vanderbilt-Ingram Cancer Center (VICC).
By VUMC News and Communications
August 18, 2016

VICC helps launch new alliance for rare kidney cancer

Children, adolescents or young adults, particularly African-Americans, diagnosed with advanced kidney cancer may actually have a rare form of the disease known as renal medullary carcinoma (RMC) that requires a specialized approach and expert intervention.
By VUMC News and Communications
1 2